SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by GlaxoSmithKline plc on December 17, 2019, for the month of December 2019. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice regarding share issuance rather than a financial results report.
Material Changes
The material event disclosed is an application to the Financial Conduct Authority and the London Stock Exchange plc for the admission of 370,000 Ordinary Shares of 25p each to the Official List. These shares are being reserved under an existing blocklisting and will be issued under the GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan. Upon issuance, the shares will rank pari passu with existing Ordinary Shares.
Guidance, Outlook, and Risks
Admission of the shares is expected to be effective on December 18, 2019. The filing contains no management commentary on financial outlook, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- 370,000 Ordinary Shares of 25p each are being issued under the 2009 Deferred Annual Bonus Plan.
- Admission to the Official List is expected to be effective on December 18, 2019.
- The new shares will rank pari passu with existing Ordinary Shares.
- No financial performance data is included in this specific filing.